---
title: Radical Resection and HIPEC for Recurrent Retroperitoneal Sarcoma
nct_id: NCT03792867
overall_status: UNKNOWN
phase: NA
sponsor: National Cancer Centre, Singapore
study_type: INTERVENTIONAL
primary_condition: Retroperitoneal Sarcoma
countries: Singapore
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03792867.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03792867"
ct_last_update_post_date: 2023-10-11
last_seen_at: "2026-05-12T07:19:10.913Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Radical Resection and HIPEC for Recurrent Retroperitoneal Sarcoma

**Official Title:** Radical Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of High Risk Recurrent Retroperitoneal Sarcoma

**NCT ID:** [NCT03792867](https://clinicaltrials.gov/study/NCT03792867)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 5
- **Lead Sponsor:** National Cancer Centre, Singapore
- **Conditions:** Retroperitoneal Sarcoma
- **Start Date:** 2018-07-23
- **Completion Date:** 2024-03-31
- **CT.gov Last Update:** 2023-10-11

## Brief Summary

Retroperitoneal sarcoma is a rare cancer that accounts for 15% of soft tissue sarcomas and affects many young people. In approximately 50% of patients, the tumour will reappear in the same area regardless of therapy. Current treatment involves radical resection; however, it does not significantly reduce recurrence rates or improve overall survival. Recurrent retroperitoneal sarcoma does not respond well to chemotherapy and prognosis is often guarded. One of the main challenges in the surgical treatment of this disease is the ability to accurately identify the local extension of the disease and to prevent local recurrence.

At present, there are no options to prevent recurrence after surgery. In recent years, there has been increased interest in the use of combined radical surgery with heated intraperitoneal chemotherapy (HIPEC). Radical resection is defined as en-bloc resection of the tumour including but not limited to surrounding organ resection and normal fat. This is in combination with the use of HIPEC. HIPEC is the use of chemotherapy in the intraperitoneal cavity that is heated to 40 to 42 degree Celsius.

Surgery coupled with HIPEC has shown to reduce recurrence in colorectal cancer, appendiceal cancer and mesothelioma. We hypothesize that HIPEC when coupled with radical surgery will improve the overall outcomes of patients with retroperitoneal sarcomatosis. We hope to learn if this treatment approach will increase locoregional control to reduce recurrence rates and improve survival.

## Eligibility

- **Minimum age:** 21 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Disease Characteristics

   1. Histologically proven soft tissue sarcoma of one of following high-risk groups:

      * Tumours with grade 2 or 3 histology
      * Size more than or equal to 5cm
      * Extracompartmental and deep extension
   2. Local recurrence of primary tumour
   3. Inadequate surgical excision of previously operated on tumour
   4. Proven diagnosis of recurrent retroperitoneal sarcoma confirmed by imaging modality and/ or intraoperative biopsy
2. Patient Characteristics

   1. Age: ≥21 years old
   2. Performance status: ECOG 0-1
   3. Normal haematological, hepatic, coagulation, renal and electrolyte profiles
   4. Normal left ventricular ejection fraction
   5. Not pregnant or nursing

Exclusion Criteria:

1. Patient is medically unfit for surgery due to concurrent medical comorbidities.
2. Any medical or psychiatric condition(s) which would preclude informed consent.
3. Patient is pregnant or nursing.
```

## Arms

- **Radical Resection and HIPEC** (EXPERIMENTAL)

## Interventions

- **Doxorubicin** (DRUG) — Immediately after resection, 15mg/m2 doxorubicin will be administered by peritoneal perfusion for 60 minutes and then drained.

## Primary Outcomes

- **Incidence of treatment-related adverse events** _(time frame: From time of resection to one year post-surgery)_ — To evaluate chemotherapy toxicity and unforeseen acute and late complications associated with the treatment

## Secondary Outcomes

- **Local recurrence-free survival** _(time frame: From time of resection until first occurrence of disease recurrence, up to 3 years)_
- **Overall survival** _(time frame: From time of resection to death from any cause, up to 3 years)_

## Locations (1)

- National Cancer Centre Singapore, Singapore, Singapore

## Recent Field Changes (last 30 days)

- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.national cancer centre singapore|singapore||singapore` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03792867.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03792867*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*